Real-World Clinical Experience of First-Line Ribociclib Combined with an Aromatase Inhibitor in Metastatic Breast Cancer
The results in terms of PFS and AEs are consistent with those of pivotal studies and real clinical practice data, but a direct comparison is not possible due to differences in patient populations. Ribociclib once again demonstrated efficacy in all patient subgroups and remains the gold standard, alongside ET, for first-line HR+/HER2-negative mBC.
Authors
- Ana Stojković (ORCID: https://orcid.org/0000-0002-2043-7424)
- Kristina Janković
- Ana S. Cvetanović
- Lazar Popović (ORCID: https://orcid.org/0000-0002-3278-6875)
- Miloš Kostić (ORCID: https://orcid.org/0000-0003-2839-3910)
Institutions
- University of Nis (RS)
- University of Novi Sad (RS)
- Oncology Institute of Vojvodina (RS)
Publication Details
- Journal
- Cancers
- Published
- 2026-01-13
- DOI
- https://doi.org/10.3390/cancers18020242
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00